Home/Filings/4/0001104659-21-146396
4//SEC Filing

Korbel Gregory Alan 4

Accession 0001104659-21-146396

CIK 0001781983other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 5:01 PM ET

Size

8.9 KB

Accession

0001104659-21-146396

Insider Transaction Report

Form 4
Period: 2021-12-01
Korbel Gregory Alan
VP of Business Dev't
Transactions
  • Exercise/Conversion

    Common Stock

    2021-12-01$0.92/sh+27,500$25,30044,667 total
  • Exercise/Conversion

    Stock Option (right to Buy)

    2021-12-0127,5002,335 total
    Exercise: $0.92Exp: 2027-02-16Common Stock (27,500 underlying)
  • Sale

    Common Stock

    2021-12-01$3.96/sh27,500$108,90017,167 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.12 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]This option was granted on February 26, 2017 and is fully exercisable.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother

Related Parties

1
  • filerCIK 0001789032

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:01 PM ET
Size
8.9 KB